These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4371987)

  • 1. Studies on viomycin. VII. Oxidative modifications of viomycin.
    Kitagawa T; Miura T; Sawada Y; Fujiwara K; Ito R
    Chem Pharm Bull (Tokyo); 1974 Aug; 22(8):1827-34. PubMed ID: 4371987
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on viomycin IX. Amino acid derivatives on viomycin.
    Kitagawa T; Miura T; Takaishi C; Taniyama H
    Chem Pharm Bull (Tokyo); 1976 Jun; 24(6):1324-30. PubMed ID: 191204
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on viomycin. VIII. Selective modifications of the terminal amino groups of viomycin.
    Kitagawa T; Miura T; Takaishi M; Taniyama H
    Chem Pharm Bull (Tokyo); 1975 Sep; 23(9):2123-7. PubMed ID: 171092
    [No Abstract]   [Full Text] [Related]  

  • 4. 13C-nuclear magnetic magnetic resonance studies on viomycin and its related compounds.
    Kitagawa T; Miura T; Mori K; Taniyama H; Kawano K; Kyogoku Y
    Chem Pharm Bull (Tokyo); 1977 Feb; 25(2):280-4. PubMed ID: 192477
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationships between antimicrobial activities and chemical structures of reduced products of viomycin.
    Kitagawa T; Miura T; Tanaka S; Taniyama H
    J Antibiot (Tokyo); 1973 Sep; 26(9):528-31. PubMed ID: 4365319
    [No Abstract]   [Full Text] [Related]  

  • 6. [Derivatives of viomycin. V. Di(oxytetracyclinemethyl)viomycin and tri(oxytetracyclinemethyl)viomycin, preparation and properties].
    Sobiczewski W; Cieślak J; Chojnowski W; Waszkiewicz A
    Acta Pol Pharm; 1969; 26(3):237-40. PubMed ID: 4308291
    [No Abstract]   [Full Text] [Related]  

  • 7. [Derivatives of viomycin. I. Preparation and properties of viomycin nicotinate and isonicotinate].
    Sobiczewski W; Cieślak J; Waszkiewicz A; Chojnowski W
    Acta Pol Pharm; 1968; 25(4):403-5. PubMed ID: 4299475
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationships between antimicrobial activities and chemically reactive functions in viomycin.
    Kitagawa T; Miura T; Tanaka S; Taniyama H
    J Antibiot (Tokyo); 1972 Jul; 25(7):429-31. PubMed ID: 4350197
    [No Abstract]   [Full Text] [Related]  

  • 9. [Derivatives of viomycin. 3. Viomycin-methyltetracyclines, their preparation and properties].
    Sobiczewski W; Chojnowski W; Waszkiewicz A
    Acta Pol Pharm; 1968; 25(6):563-7. PubMed ID: 4307876
    [No Abstract]   [Full Text] [Related]  

  • 10. [In vitro sensitivity of various micro-organisms from animal sources to viomycin].
    DEOM J; MORTELMANS J
    Antonie Van Leeuwenhoek; 1955; 21(4):377-81. PubMed ID: 13327858
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101,680 and CP-163,234, for animal health use.
    Norcia LJ; Silvia AM; Dirlam JP; Schnur RC; Bergeron JM; Retsema JA; Hayashi SF
    J Antibiot (Tokyo); 1999 Nov; 52(11):1007-16. PubMed ID: 10656573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viomycin derivatives. IV. Preparation and properties of some penicillinates].
    Sobiczewski W; Cieślak J; Chojnowski W; Waszkiewicz A; Cendrowska H
    Acta Pol Pharm; 1969; 26(1):29-32. PubMed ID: 4305691
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on viomycin. XIV. Roles of basic and cyclic moieties in the antimicrobial activity of viomycin.
    Kitagawa T; Miura T; Kurose H
    Chem Pharm Bull (Tokyo); 1979 Nov; 27(11):2551-6. PubMed ID: 230912
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on oxidative modifications of nucleic acid pyrimidine bases.
    Harayama T; Yanada R; Kotoji K; Yoneda F; Taga T; Osaki K; Nagamatsu T
    Nucleic Acids Symp Ser; 1984; (15):1-4. PubMed ID: 6522278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Derivatives of viomycin. II. Preparation and properties of some viomycin penicillinates].
    Sobiczewski W; Cieślak J; Chojnowski W; Waszkiewicz A; Cendrowska H
    Acta Pol Pharm; 1968; 25(4):407-10. PubMed ID: 4299476
    [No Abstract]   [Full Text] [Related]  

  • 16. [Studies of some viomycinmethyltetracyclines].
    Sobiczewski W; Cendrowska H; Chojnowski W
    Acta Pol Pharm; 1969; 26(6):505-10. PubMed ID: 4314647
    [No Abstract]   [Full Text] [Related]  

  • 17. Catalytic hydrogenation of viomycin and capreomycin.
    Dyer JR; Carter JH; van Wyk PJ
    J Med Chem; 1971 Nov; 14(11):1120-1. PubMed ID: 4329900
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of kanamycin, viomycin and capreomycin resistance of Mycobacterium tuberculosis].
    Tomoda T; Minami Y; Maekawa Y; Oi Y
    Rinsho Byori; 1971 Jun; 19(6):423-6. PubMed ID: 4111341
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical tests of viomycin-pantothenatesulfate (vionactan-P)].
    ARNOLD M
    Schweiz Z Tuberc Pneumonol; 1958; 15(4):203-10. PubMed ID: 13602779
    [No Abstract]   [Full Text] [Related]  

  • 20. [Viomycin and viomycin pantothenate with reduced toxicity in therapy of pulmonary tuberculosis].
    KUNTZ E
    Arzneimittelforschung; 1957 Apr; 7(4):233-7. PubMed ID: 13436325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.